Joinn Laboratories (06127) announces its performance in 2024, with a net profit attributable to equity shareholders of 74.075 million yuan, a year-on-year decrease of 81.3%.
Zhao Yan New Medicine (06127) announced its performance in 2024, with revenue of about 2.018 billion yuan, a decrease of 15.1% year-on-year.
Joinn Laboratories (06127) announced its performance for 2024, with revenue of approximately 2.018 billion yuan, a year-on-year decrease of 15.1%; gross profit of approximately 506 million yuan, a year-on-year decrease of 48.4%; net profit attributable to equity shareholders of the company of 74.075 million yuan, a year-on-year decrease of 81.3%; and earnings per share of 0.1 yuan. During the reporting period, the company's overall order backlog amounted to approximately 2.2 billion yuan, with signed orders totaling approximately 1.84 billion yuan.
The announcement stated that the decrease in revenue was mainly driven by increased competition leading to a decline in unit prices for projects.
Related Articles
As of the end of May, the net asset value per share of Capital Realm (00204) is approximately 0.267 Hong Kong dollars.
New stock news | Golden Leaf International submitted an application to the Hong Kong Stock Exchange as a well-established contractor for mechanical and electrical engineering.
GF Securities: How do you view the continued narrowing of the premium rate for A and H shares?
As of the end of May, the net asset value per share of Capital Realm (00204) is approximately 0.267 Hong Kong dollars.
New stock news | Golden Leaf International submitted an application to the Hong Kong Stock Exchange as a well-established contractor for mechanical and electrical engineering.
GF Securities: How do you view the continued narrowing of the premium rate for A and H shares?
